Prediction of drug responses in schizophrenia: A method using a test dose of chlorpromazine

Psychiatry and Clinical Neurosciences

Volumn 51, Issue 4, 1997, Pages 217-222

  Minami, Hideo ^a   Nakahara, Tadahiko ^b   Miyahara, Akio ^b   Nakane, Yoshibumi ^b  

^a Nagasaki Municipal Hospital   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chlorpromazine; Discriminant analysis; Drug monitoring; Drug therapy; Haloperidol; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CHLORPROMAZINE SULFOXIDE; DRUG METABOLITE; HALOPERIDOL;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; CHROMATOGRAPHY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LIVER DYSFUNCTION; MALE; PREDICTION; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0030818748     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.1997.tb02586.x     Document Type: Article

References (20)

1. Ødegard Ø. Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of psychotropic drugs. Am. J. Psychiatry 1964; 120: 772-778.
2. Peterson DB, Olson GW. First admitted schizophrenics in the drug era. Arch. Gen. Psychiatry 1964; 11: 137-144.
3. Prichard DM. Prognosis of schizophrenia before and after pharmacotherapy: I. Short-term outcome. Br. J. Psychiatry 1967; 113: 1345-1352.
4. Prichard DM. Prognosis of schizophrenia before and after pharmacotherapy: II. Three-year follow-up, Br.. J. Psychiatry 1967; 113: 1353-1359.
5. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 1991; 17: 325-351.
6. Zemlan FP, Thienhaus OJ, Garver DL. Length of psychiatric hospitalization and prediction of antipsychotic response. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990; 14: 13-24.
7. Nedopil N, Rüther E. Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatry 1981; 14: 205-207.
8. Sakurai Y, Nakahara T, Takahashi R. Prediction of response to chlopromazine treatment in schizophrenia. Psychopharmacologia 1975; 44: 195-203.
9. Sakurai Y, Takahashi R. Nakahara T, Ikenaga H. Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients. Arch. Gen. Psychiatry 1980; 37: 1057-1062.
10. Lydiard RB, Laird LK. Prediction of response to antipsychotics. J. Clin. Psychopharmacol. 1988; 8: 3-13.
11. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962; 10: 799-812.
12. Curry SH. Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector. Anal. Chem. 1968; 40: 1251-1256.
13. Itoh H. Pharmacotherapy of schizophrenia: Its present status and controversial points. Seishin-igaku 1985; 27: 521-530 (in Japanese).
14. Petrie EC, Faustman WO, Moses JA, Lombrozo L, Csernansky JG. Correlates of rapid neuroleptic response in male patients with schizophrenia. Psychiatry Res. 1990; 33: 171-177.
15. Goldberg SC, Mattsson N, Cole JO, Klerman GL. Prediction of improvement in schizophrenia under four phenothiazines. Arch. Gen. Psychiatry 1967; 16: 107-117.
16. Hogarty GE, Goldberg SC, Schooler NR et al. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch. Gen. Psychiatry 1974; 31: 603-609.
17. Wong DF, Wagner HN Jr, Dannals RF et al. Effect of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 1393-1396.
18. May PRA, van Putten T, Yale C et al. Predicting individual responses to drug treatment in schizophrenia: A test dose model. J. Nerv. Ment. Dis. 1976; 162: 177-183.
19. Gaebel W, Müller-Oerlinghausen B, Schley UJ. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 1992; 16: 891-900.
20. Wolkowitz OM, Bartko JJ, Pickar D. Drug trials and heterogeneity in schizophrenia: The mean is not the end. Biol. Psychiatry 1990; 28: 1021-1025.